Exact Sciences (EXAS) Soars 3.62% to Record High on Strategic Advancements, Revenue Surge

Exact Sciences (EXAS) shares surged to a new peak on October 9, 2025, hitting a level not seen since October 2025, with an intraday gain of 3.62%. The stock has climbed 5.57% over the past four trading days, extending a four-day winning streak, as investor confidence in the company’s growth prospects appears to be gaining momentum.

The rally aligns with recent strategic advancements, including the launch of Cologuard Plus in Q1 2025, which enhances colorectal cancer screening accuracy by nearly 40% and benefits from Medicare coverage and inclusion in national guidelines. Additionally, the company’s Oncodetect test, introduced in April 2025, leverages whole exome sequencing to detect residual cancer DNA earlier than imaging, further solidifying its position in the precision oncology market. These product innovations have bolstered revenue, with Q2 2025 results showing a 16% year-over-year revenue increase to $811 million and adjusted EBITDA rising 26% to $138 million.

Analysts highlight the stock’s current undervaluation, with a fair value estimate of $65.38 suggesting a 11.7% discount. This assessment factors in anticipated margin improvements, Medicare coverage for key tests, and the potential of Cancerguard™—a multi-cancer early detection test expected to launch as an LDT in September 2025. However, challenges remain, including reliance on Cologuard for a significant revenue share and uncertainties around adoption rates for newer tests like Cancerguard and Oncodetect.

Exact Sciences has also expanded its pipeline through strategic partnerships, such as exclusive rights to Freenome’s blood-based colorectal cancer tests and a sublicense for TwinStrand Biosciences’ sequencing technology. These moves aim to diversify diagnostic offerings and enhance genomic research capabilities. Despite these strengths, risks such as regulatory hurdles, competitive pressures, and reimbursement uncertainties for novel tests could temper long-term growth. Investors are now weighing whether the current valuation reflects realistic potential or if further upside remains as the company executes its expansion and product launch roadmap.